SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
|Articles|January 1, 2004
FDA panel recommends label change
Author(s)John Jesitus
Washington, D.C. - Responding to concerns over increased malignancies seen in animal studies, a pediatric subcommittee of the FDA's Anti-Infective Drugs Advisory Committee said topical immunosuppressant labeling should include a warning against use in children under the age of two.
Advertisement
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Advertisement
Advertisement